Prevenar 13 Vaccine is a Pneumococcal conjugate vaccine used to prevent infections caused by the bacterium Streptococcus pneumoniae. It is intended to provide protection against 13 different pneumococcus bacterial serotypes. 

Brand Name: Prevenar

Composition: Pneumococcal conjugate vaccine

Mechanism of Action:

Streptococcus pneumoniae polysaccharide antigens conjugated to the CRM197 carrier protein are presented to the immune system by Prevenar 13. This results in the generation of particular antibodies against 13 pneumococcal serotypes by activating B-cells in a T-cell-dependent manner. These antibodies prevent colonization, encourage phagocytosis, and neutralize microorganisms. Additionally, the vaccine creates immunological memory that lasts for quick reactions in the future.

Uses:

·       Pneumonia

·       Meningitis

·       Bacteremia

·       Otitis media (middle ear infections)

Dosage and Administration:

The vaccine is given as an intramuscular injection.

Side Effects:

·       Sleepiness

·       Injection site reactions (pain, swelling, redness)

·       Decreased appetite

·       Irritability

·       Rash

·       Sleep deprivation

·       Vomiting

·       Diarrhea

·       Fever

·       Chills

Safety Advise:

Liver  

The safety of Prevenar Vaccine for individuals with liver issues is uncertain. Kindly speak with your healthcare provider.

Kidney  

The safety of Prevenar Vaccine for individuals with Kidney issues is uncertain. Kindly speak with your healthcare provider.

Pregnancy  

Prevenar Vaccine should be used during pregnancy only if clearly needed, Kindly speak with your healthcare provider.

Breast Feeding  

Using Prevenar Vaccine while nursing is most likely dangerous. Kindly speak with your healthcare provider. 

Storage:

Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.

How to use this Medication?

The pneumococcal conjugate vaccination (PCV15 or PCV20) is typically administered in four doses to infants and young children at the ages of two, four, six, and twelve to fifteen months.

If they did not receive the necessary doses as babies and young children, children aged 24 to 59 months may be eligible to receive the pneumococcal conjugate vaccination.

Pneumococcal conjugate vaccination may be necessary for children and adolescents aged 6-18 with specific medical conditions if they have not previously received the recommended doses of PCV13, PCV15, or PCV20.

A different kind of pneumococcal conjugate vaccine may be required for certain adults who have previously received one. You can get further details from your healthcare provider.

References:

1.     Duggan ST. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)[prevenar 13®]. Drugs. 2010 Oct;70(15):1973-86.

2.  Sucher AJ, Chahine EB, Nelson M, Sucher BJ. Prevnar 13, the new 13-valent pneumococcal conjugate vaccine. Annals of Pharmacotherapy. 2011     Dec;45(12):1516-24.

3.     Duggan ST. Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed)[Prevenar 13®] Profile Report. Pediatric Drugs. 2012 Feb;14(1):67-9.

Disclaimer:

The main goal of Apothecare Wellness is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare Wellness, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place.